JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

NCT06386146 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: JAB-30355
DRUG: JAB-30355

Sponsor

Jacobio Pharmaceuticals Co., Ltd.